Literature DB >> 17624600

Roles and responsibilities of a medical geneticist.

Wendy S Rubinstein1.   

Abstract

Medical geneticists must generate a differential diagnosis, practice evidence-based medicine, and apply ethical, legal, and social issue (ELSI) principles in the clinical setting. Several clinical scenarios are presented which illustrate dilemmas in the cancer genetics setting. These include the differential diagnosis of breast and gastric cancer, and the predicament posed by the need to practice evidence-based medicine in light of limitations in the medical genetics literature, which may mean recommending prophylactic surgery. Also discussed are three BRCA1/2 genetic testing scenarios which illustrate the difficulty of knowing where to "draw the line", i.e., when to offer testing and what level of testing to pursue. Decision-making about BRCA1/2 gene testing including Ashkenazi Jewish founder mutation testing, comprehensive reflex testing, and expedited testing, is explored. The duty to recontact as standard of care evolves requires that medical geneticists determine how to prospectively set expectations with patients as well as to decide which situations require recontact and to determine how to systematically do so. The case of patient recontact regarding new mutation detection techniques with improved sensitivity, e.g., BART testing which is based on the ability to detect large BRCA1/2 rearrangements, is discussed. General principles are highlighted so that these specific cases can be extrapolated to other genes and hereditary conditions by medical geneticists, genetic counselors, and others practicing in the field of cancer genetics.

Entities:  

Mesh:

Year:  2007        PMID: 17624600     DOI: 10.1007/s10689-007-9148-6

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  16 in total

1.  Practicing medicine at the front lines of the genomic revolution.

Authors:  Wendy S Rubinstein; Hemant K Roy
Journal:  Arch Intern Med       Date:  2005-09-12

2.  The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features.

Authors:  Gershon Y Locker; Karen Kaul; David S Weinberg; Zoran Gatalica; Gordon Gong; Amy Peterman; Jane Lynch; Lucy Klatzco; Olufunmilayo I Olopade; Charles A Bomzer; Anna Newlin; Eileen Keenan; Mohammed Tajuddin; Joseph Knezetic; Stephanie Coronel; Henry T Lynch
Journal:  Cancer Genet Cytogenet       Date:  2006-08

3.  Evidence based medicine: what it is and what it isn't.

Authors:  D L Sackett; W M Rosenberg; J A Gray; R B Haynes; W S Richardson
Journal:  BMJ       Date:  1996-01-13

4.  The duty to recontact: attitudes of genetics service providers.

Authors:  J L Fitzpatrick; C Hahn; T Costa; M J Huggins
Journal:  Am J Hum Genet       Date:  1999-03       Impact factor: 11.025

5.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.

Authors:  G Parmigiani; D Berry; O Aguilar
Journal:  Am J Hum Genet       Date:  1998-01       Impact factor: 11.025

6.  Cancer Incidence in BRCA1 mutation carriers.

Authors:  Deborah Thompson; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

7.  Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

Authors:  Marcia S Brose; Timothy R Rebbeck; Kathleen A Calzone; Jill E Stopfer; Katherine L Nathanson; Barbara L Weber
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

Review 8.  Mathematical modeling for breast cancer risk assessment. State of the art and role in medicine.

Authors:  Wendy S Rubinstein; Suzanne M O'Neill; June A Peters; Laura J Rittmeyer; Mona P Stadler
Journal:  Oncology (Williston Park)       Date:  2002-08       Impact factor: 2.990

9.  A family with three germline mutations in BRCA1 and BRCA2.

Authors:  A Liede; K Metcalfe; K Offit; K Brown; S Miller; S A Narod; R Moslehi
Journal:  Clin Genet       Date:  1998-09       Impact factor: 4.438

10.  Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.

Authors:  Tom Walsh; Silvia Casadei; Kathryn Hale Coats; Elizabeth Swisher; Sunday M Stray; Jake Higgins; Kevin C Roach; Jessica Mandell; Ming K Lee; Sona Ciernikova; Lenka Foretova; Pavel Soucek; Mary-Claire King
Journal:  JAMA       Date:  2006-03-22       Impact factor: 56.272

View more
  8 in total

1.  Challenges for providing genetic counselling in Colombian genetic clinics: the viewpoint of the physicians providing genetic consultations.

Authors:  Clemencia Rodas-Pérez; Angus Clarke; John Powell; Margaret Thorogood
Journal:  J Community Genet       Date:  2015-06-19

2.  BRCA sequencing and large rearrangement testing in young Black women with breast cancer.

Authors:  Tuya Pal; Devon Bonner; Deborah Cragun; Sharland Johnson; Mohammad Akbari; Lily Servais; Steven Narod; Susan Vadaparampil
Journal:  J Community Genet       Date:  2013-08-29

3.  Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.

Authors:  Brian S Finkelman; Wendy S Rubinstein; Sue Friedman; Tara M Friebel; Shera Dubitsky; Niecee Singer Schonberger; Rochelle Shoretz; Christian F Singer; Joanne L Blum; Nadine Tung; Olufunmilayo I Olopade; Jeffrey N Weitzel; Henry T Lynch; Carrie Snyder; Judy E Garber; Joellen Schildkraut; Mary B Daly; Claudine Isaacs; Gabrielle Pichert; Susan L Neuhausen; Fergus J Couch; Laura van't Veer; Rosalind Eeles; Elizabeth Bancroft; D Gareth Evans; Patricia A Ganz; Gail E Tomlinson; Steven A Narod; Ellen Matloff; Susan Domchek; Timothy R Rebbeck
Journal:  J Clin Oncol       Date:  2012-03-19       Impact factor: 44.544

4.  Detection of BRCA1 and BRCA2 Ashkenazi Jewish founder mutations in formalin-fixed paraffin-embedded tissues using conventional PCR and heteroduplex/amplicon size differences.

Authors:  Kathy A Mangold; Vivien Wang; Scott M Weissman; Wendy S Rubinstein; Karen L Kaul
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

5.  Family physicians' management of genetic aspects of a cardiac disease: a scenario-based study from slovenia.

Authors:  Z Klemenc-Ketiš; B Peterlin
Journal:  Balkan J Med Genet       Date:  2014-12-11       Impact factor: 0.519

6.  Recontacting in clinical practice: an investigation of the views of healthcare professionals and clinical scientists in the United Kingdom.

Authors:  Daniele Carrieri; Sandi Dheensa; Shane Doheny; Angus J Clarke; Peter D Turnpenny; Anneke M Lucassen; Susan E Kelly
Journal:  Eur J Hum Genet       Date:  2017-01-04       Impact factor: 4.246

Review 7.  Is there a duty to recontact in light of new genetic technologies? A systematic review of the literature.

Authors:  Ellen Otten; Mirjam Plantinga; Erwin Birnie; Marian A Verkerk; Anneke M Lucassen; Adelita V Ranchor; Irene M Van Langen
Journal:  Genet Med       Date:  2014-12-11       Impact factor: 8.822

8.  Recontacting in clinical practice: the views and expectations of patients in the United Kingdom.

Authors:  Daniele Carrieri; Sandi Dheensa; Shane Doheny; Angus J Clarke; Peter D Turnpenny; Anneke M Lucassen; Susan E Kelly
Journal:  Eur J Hum Genet       Date:  2017-08-02       Impact factor: 4.246

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.